Form 4: Beta Bionics CFO Exercises, Sells Shares Under 10b5-1 Plan

Beta Bionics' Chief Financial Officer, Stephen Feider, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 plan.

Summary

• Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (BBNX), engaged in transactions involving the company's common stock on October 1, 2025.
• Feider exercised employee stock options to acquire 15,018 shares of common stock at an exercise price of $5.10 per share.
• Immediately following the exercise, he sold 14,918 shares at a weighted average price of $20.76 per share, with prices ranging from $20.03 to $21.03.
• An additional 100 shares were sold at a price of $21.08 per share.
• All sales were conducted pursuant to a Rule 10b5-1 Plan, which was adopted on May 15, 2025.
• Following these transactions, Feider's direct beneficial ownership of common stock remained at 44,041 shares, while his beneficial ownership of employee stock options decreased to 74,677.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it involves insider selling, it's a pre-arranged 10b5-1 plan, which is a routine financial planning event for executives. The significant profit realized by the CFO is a positive for the individual.

Positives

• The Chief Financial Officer realized a significant profit from the exercise of options and subsequent sale of shares, with an average sale price substantially higher than the exercise price.
• The transactions were executed under a pre-arranged Rule 10b5-1 Plan, indicating a planned and transparent approach to insider trading.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market, although the pre-arranged nature mitigates this concern.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine insider transaction report and does not provide specific insights into broader industry trends or competitive landscape. It reflects an individual executive's financial planning.

Stakeholder Impact

• Shareholders: May view the insider selling as a routine event given the 10b5-1 plan, or potentially as a signal of an executive taking profits, which is common. The net beneficial ownership of common stock remained unchanged after the transactions, while options decreased.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The filing details a routine insider transaction under a pre-arranged 10b5-1 plan, where the CFO exercised options and sold the resulting shares for a profit. Such transactions are typically part of an executive's personal financial planning and do not usually indicate a change in the company's fundamental outlook or warrant a significant shift in investment recommendation. Therefore, a 'hold' recommendation is appropriate, as this specific filing does not provide new information to alter the existing investment thesis.

Keywords

Beta Bionics, BBNX, insider trading, Form 4, stock option exercise, share sale, Stephen Feider, CFO, 10b5-1 plan